Skip to main content
Top
Published in: Inflammation 1/2015

01-02-2015

Intra-articular (IA) Ropivacaine Microparticle Suspensions Reduce Pain, Inflammation, Cytokine, and Substance P Levels Significantly More than Oral or IA Celecoxib in a Rat Model of Arthritis

Authors: Barrett Rabinow, Jane Werling, Alison Bendele, Jerome Gass, Roy Bogseth, Kelly Balla, Paul Valaitis, Audrey Hutchcraft, Sabine Graham

Published in: Inflammation | Issue 1/2015

Login to get access

ABSTRACT

Current therapeutic treatment options for osteoarthritis entail significant safety concerns. A novel ropivacaine crystalline microsuspension for bolus intra-articular (IA) delivery was thus developed and studied in a peptidoglycan polysaccharide (PGPS)-induced ankle swelling rat model. Compared with celecoxib controls, both oral and IA, ropivacaine IA treatment resulted in a significant reduction of pain upon successive PGPS reactivation, as demonstrated in two different pain models, gait analysis and incapacitance testing. The reduction in pain was attended by a significant reduction in histological inflammation, which in turn was accompanied by significant reductions in the cytokines IL-18 and IL-1β. This may have been due to inhibition of substance P, which was also significantly reduced. Pharmacokinetic analysis indicated that the analgesic effects outlasted measurable ropivacaine levels in either blood or tissue. The results are discussed in the context of pharmacologic mechanisms both of local anesthetics as well as inflammatory arthritis.
Literature
1.
go back to reference Chou R. 2011. Oregon evidence-based practice center analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. AHRQ Pub No 11(12)-EHC076-EF. Chou R. 2011. Oregon evidence-based practice center analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. AHRQ Pub No 11(12)-EHC076-EF.
2.
go back to reference Bijlsma, J. 2010. Patient benefit-risk in arthritis—a rheumatologist’s perspective. Rheumatology (Oxford) 49(Suppl 2): ii11–ii17. Bijlsma, J. 2010. Patient benefit-risk in arthritis—a rheumatologist’s perspective. Rheumatology (Oxford) 49(Suppl 2): ii11–ii17.
3.
go back to reference Crilly, M., A. Mangoni, and K. Knights. 2013. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 31: 691–698.PubMed Crilly, M., A. Mangoni, and K. Knights. 2013. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 31: 691–698.PubMed
4.
go back to reference Upadhyay, J., S. Baker, R. Rajagovindan, M. Hart, P. Chandran, B. Hooker, S. Cassar, J. Mikusa, A. Tovcimak, M. Wald, et al. 2013. Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. NeuroImage 64: 341–355.CrossRefPubMed Upadhyay, J., S. Baker, R. Rajagovindan, M. Hart, P. Chandran, B. Hooker, S. Cassar, J. Mikusa, A. Tovcimak, M. Wald, et al. 2013. Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. NeuroImage 64: 341–355.CrossRefPubMed
5.
go back to reference Andersen, L., B. Kristensen, H. Husted, K. Otte, and H. Kehlet. 2008. Local anesthetics after total knee arthroplasty: intraarticular or extraarticular administration? A randomized, double-blind, placebo-controlled study. Acta Orthopaedica 79: 800–805.CrossRefPubMed Andersen, L., B. Kristensen, H. Husted, K. Otte, and H. Kehlet. 2008. Local anesthetics after total knee arthroplasty: intraarticular or extraarticular administration? A randomized, double-blind, placebo-controlled study. Acta Orthopaedica 79: 800–805.CrossRefPubMed
6.
go back to reference Toda, S., A. Sakai, Y. Ikeda, A. Sakamoto, and H. Suzuki. 2011. A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain. Molecular Pain 7: 2.CrossRefPubMedCentralPubMed Toda, S., A. Sakai, Y. Ikeda, A. Sakamoto, and H. Suzuki. 2011. A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain. Molecular Pain 7: 2.CrossRefPubMedCentralPubMed
7.
go back to reference Blumenthal, S. 2006. Ropivacaine decreases inflammation in experimental endotoxin-induced lung injury. Anesthesiology 104: 961–969.CrossRefPubMed Blumenthal, S. 2006. Ropivacaine decreases inflammation in experimental endotoxin-induced lung injury. Anesthesiology 104: 961–969.CrossRefPubMed
8.
go back to reference Creamer, P., M. Hunt, and P. Dieppe. 1996. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. The Journal of Rheumatology 23: 1031–1036.PubMed Creamer, P., M. Hunt, and P. Dieppe. 1996. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. The Journal of Rheumatology 23: 1031–1036.PubMed
9.
go back to reference Gazi, M., A. Issy, and R. Sakata. 2005. Intra-articular bupivacaine and morphine for knee osteoarthritis analgesia. Comparative study. Rev Bras Anestesiol 55: 491–499.CrossRefPubMed Gazi, M., A. Issy, and R. Sakata. 2005. Intra-articular bupivacaine and morphine for knee osteoarthritis analgesia. Comparative study. Rev Bras Anestesiol 55: 491–499.CrossRefPubMed
10.
go back to reference MacMahon, P., S. Eustace, and E. Kavanagh. 2009. Injectable corticosteroid and local anesthetic preparations: a review for radiologists. Radiology 252: 647.CrossRefPubMed MacMahon, P., S. Eustace, and E. Kavanagh. 2009. Injectable corticosteroid and local anesthetic preparations: a review for radiologists. Radiology 252: 647.CrossRefPubMed
11.
go back to reference Rabinow, B. 2004. Nanosuspensions in drug delivery. Nature Rev Drug Discovery 3: 785–796.CrossRef Rabinow, B. 2004. Nanosuspensions in drug delivery. Nature Rev Drug Discovery 3: 785–796.CrossRef
12.
go back to reference Teeple, E., G. Jay, K. Elsaid, and B. Fleming. 2013. Animal models of osteoarthritis: challenges of model selection and analysis. AAPS Journal 15: 438–446.CrossRefPubMedCentralPubMed Teeple, E., G. Jay, K. Elsaid, and B. Fleming. 2013. Animal models of osteoarthritis: challenges of model selection and analysis. AAPS Journal 15: 438–446.CrossRefPubMedCentralPubMed
13.
go back to reference Neugebauer, V., J. Han, H. Adwanikar, Y. Fu, and G. Ji. 2007. Techniques for assessing knee joint pain in arthritis. Molecular Pain 3: 1–13.CrossRef Neugebauer, V., J. Han, H. Adwanikar, Y. Fu, and G. Ji. 2007. Techniques for assessing knee joint pain in arthritis. Molecular Pain 3: 1–13.CrossRef
14.
go back to reference Bendele, A. 2001. Animal models of rheumatoid arthritis. Journal of Musculoskeletal and Neuronal Interactions 1: 377–385.PubMed Bendele, A. 2001. Animal models of rheumatoid arthritis. Journal of Musculoskeletal and Neuronal Interactions 1: 377–385.PubMed
15.
16.
go back to reference Goldring, M. 2000. Osteoarthritis and cartilage: the role of cytokines. Current Rheumatology 2: 459–465.CrossRef Goldring, M. 2000. Osteoarthritis and cartilage: the role of cytokines. Current Rheumatology 2: 459–465.CrossRef
17.
go back to reference Westacott, C., and M. Sharif. 1996. Cytokines in osteoarthritis: mediators or markers of joint destruction? Seminars in Arthritis and Rheumatism 25: 254–272.CrossRefPubMed Westacott, C., and M. Sharif. 1996. Cytokines in osteoarthritis: mediators or markers of joint destruction? Seminars in Arthritis and Rheumatism 25: 254–272.CrossRefPubMed
18.
go back to reference Vincent, T., R. Williams, R. Maciewicz, A. Silman, and P. Garside. 2012. Mapping pathogenesis of arthritis through small animal models. Rheumatology (Oxford) 51: 1931–1941. Vincent, T., R. Williams, R. Maciewicz, A. Silman, and P. Garside. 2012. Mapping pathogenesis of arthritis through small animal models. Rheumatology (Oxford) 51: 1931–1941.
19.
go back to reference Esser, R., S. Stimpson, W. Cromartie, and J. Schwab. 1985. Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. Arthritis & Rheumatology 28: 1402–1411.CrossRef Esser, R., S. Stimpson, W. Cromartie, and J. Schwab. 1985. Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. Arthritis & Rheumatology 28: 1402–1411.CrossRef
20.
go back to reference Schwab, J., S. Anderle, R. Brown, F. Dalldorf, and R. Thompson. 1991. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infection Immunity 59: 4436–4442.PubMedCentralPubMed Schwab, J., S. Anderle, R. Brown, F. Dalldorf, and R. Thompson. 1991. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infection Immunity 59: 4436–4442.PubMedCentralPubMed
21.
go back to reference Chan, J., G. Villarreal, W. Jn, T. Stepan, H. Burstein, and S. Wahl. 2002. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Molecular Therapy 6: 727–736.CrossRefPubMed Chan, J., G. Villarreal, W. Jn, T. Stepan, H. Burstein, and S. Wahl. 2002. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Molecular Therapy 6: 727–736.CrossRefPubMed
22.
go back to reference Dong, J., D. Jiang, Z. Wang, G. Wu, L. Miao, and L. Huang. 2013. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model. International Journal of Pharmaceutics 441: 285–290.CrossRefPubMed Dong, J., D. Jiang, Z. Wang, G. Wu, L. Miao, and L. Huang. 2013. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model. International Journal of Pharmaceutics 441: 285–290.CrossRefPubMed
23.
go back to reference Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. Washington: National Academy Press. Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. Washington: National Academy Press.
24.
go back to reference Bove, S., S. Calcaterra, R. Brooker, C. Huber, R. Guzman, P. Juneau, D. Schrier, and K. Kilgore. 2003. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis and Cartilage 11: 821–830.CrossRefPubMed Bove, S., S. Calcaterra, R. Brooker, C. Huber, R. Guzman, P. Juneau, D. Schrier, and K. Kilgore. 2003. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis and Cartilage 11: 821–830.CrossRefPubMed
25.
go back to reference Millipore Corporation. Manual for MILLIPLEX™ MAP Kit, rat cytokine/chemokine. RCYT0-80K.6-18-09. Billerica, MA. Millipore Corporation. Manual for MILLIPLEX™ MAP Kit, rat cytokine/chemokine. RCYT0-80K.6-18-09. Billerica, MA.
26.
go back to reference R&D Systems, Inc. 2008. Package insert for Parameter™ substance P assay. 7515743. Minneapolis, MN. R&D Systems, Inc. 2008. Package insert for Parameter™ substance P assay. 7515743. Minneapolis, MN.
27.
go back to reference Phoenix Pharmaceuticals, Inc. Protocol for Catalog #EK-049-03, NPY (human, rat, mouse) EIA Kit. Burlingame, CA. Phoenix Pharmaceuticals, Inc. Protocol for Catalog #EK-049-03, NPY (human, rat, mouse) EIA Kit. Burlingame, CA.
28.
go back to reference Stolina, M., B. Bolon, D. Dwyer, S. Middleton, D. Duryea, P. Kostenuik, U. Feige, and D. Zack. 2008. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 13: 692–712.CrossRefPubMed Stolina, M., B. Bolon, D. Dwyer, S. Middleton, D. Duryea, P. Kostenuik, U. Feige, and D. Zack. 2008. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 13: 692–712.CrossRefPubMed
29.
go back to reference Stolina, M., B. Bolon, S. Middleton, D. Dwyer, H. Brown, D. Duryea, L. Zhu, A. Rohner, J. Pretorius, P. Kostenuik, et al. 2009. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Journal of Clinical Immunology 29: 158–174.CrossRefPubMed Stolina, M., B. Bolon, S. Middleton, D. Dwyer, H. Brown, D. Duryea, L. Zhu, A. Rohner, J. Pretorius, P. Kostenuik, et al. 2009. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Journal of Clinical Immunology 29: 158–174.CrossRefPubMed
30.
go back to reference Szekanecz, Z., M. Halloran, M. Volin, J. Woods, R. Strieter, K. Haines 3rd, S. Kunkel, M. Burdick, and A. Koch. 2000. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis & Rheumatism 43: 1266–1277.CrossRef Szekanecz, Z., M. Halloran, M. Volin, J. Woods, R. Strieter, K. Haines 3rd, S. Kunkel, M. Burdick, and A. Koch. 2000. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis & Rheumatism 43: 1266–1277.CrossRef
31.
go back to reference Dias, M., D. Newton, G. McLeod, F. Khan, and J. Belch. 2008. The inhibitory effects of local anaesthetics on the vascular flare responses to bradykinin and substance P in human skin. Anaesthesia 63: 151–155.CrossRefPubMed Dias, M., D. Newton, G. McLeod, F. Khan, and J. Belch. 2008. The inhibitory effects of local anaesthetics on the vascular flare responses to bradykinin and substance P in human skin. Anaesthesia 63: 151–155.CrossRefPubMed
32.
go back to reference Uematsu, T., A. Sakai, H. Ito, and H. Suzuki. 2011. Intra-articular administration of tachykinin NK1 receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. European Journal of Pharmacology 668: 163–168.CrossRefPubMed Uematsu, T., A. Sakai, H. Ito, and H. Suzuki. 2011. Intra-articular administration of tachykinin NK1 receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. European Journal of Pharmacology 668: 163–168.CrossRefPubMed
33.
go back to reference Hill, R. 2000. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends in Pharmacological Sciences 21: 244–246.CrossRefPubMed Hill, R. 2000. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends in Pharmacological Sciences 21: 244–246.CrossRefPubMed
34.
go back to reference Appell, K., B. Fragale, J. Loscig, S. Singh, and B. Tomczuk. 1992. Antagonists that demonstrate species differences in neurokinin-1 receptors. Molecular Pharmacology 41: 772–778.PubMed Appell, K., B. Fragale, J. Loscig, S. Singh, and B. Tomczuk. 1992. Antagonists that demonstrate species differences in neurokinin-1 receptors. Molecular Pharmacology 41: 772–778.PubMed
35.
go back to reference Borbe, E., Z. Hajna, K. Sandor, L. Kereskai, I. Toth, and E. Pinter. 2013. Role of tachykinin 1 and 4 gene-derived neuropeptides and the neurokinin 1 receptor in adjuvant-induced chronic arthritis of the mouse. PLOS ONE 8(4): e61684.CrossRef Borbe, E., Z. Hajna, K. Sandor, L. Kereskai, I. Toth, and E. Pinter. 2013. Role of tachykinin 1 and 4 gene-derived neuropeptides and the neurokinin 1 receptor in adjuvant-induced chronic arthritis of the mouse. PLOS ONE 8(4): e61684.CrossRef
36.
go back to reference Peck, S., R. Johnston Jr., and L. Horwitz. 1985. Reduced neutrophil superoxide anion release after prolonged infusions of lidocaine. Journal of Pharmacology and Experimental Therapeutics 235: 418–422.PubMed Peck, S., R. Johnston Jr., and L. Horwitz. 1985. Reduced neutrophil superoxide anion release after prolonged infusions of lidocaine. Journal of Pharmacology and Experimental Therapeutics 235: 418–422.PubMed
37.
go back to reference Cullen, B., and R. Haschke. 1974. Local anesthetic inhibition of phagocytosis and metabolism of human leukocytes. Anesthesiology 40: 142–146.CrossRefPubMed Cullen, B., and R. Haschke. 1974. Local anesthetic inhibition of phagocytosis and metabolism of human leukocytes. Anesthesiology 40: 142–146.CrossRefPubMed
38.
go back to reference Cesar, H., and P. Marques. 2009. The use of lidocaine as an anti-inflammatory substance: a systematic review. Journal of Dentistry 37: 93–97.CrossRef Cesar, H., and P. Marques. 2009. The use of lidocaine as an anti-inflammatory substance: a systematic review. Journal of Dentistry 37: 93–97.CrossRef
39.
go back to reference Scott, D., A. Lee, D. Fagan, G. Bowler, P. Bloomfield, and R. Lundh. 1989. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesthesia & Analgesia 69: 563–569. Scott, D., A. Lee, D. Fagan, G. Bowler, P. Bloomfield, and R. Lundh. 1989. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesthesia & Analgesia 69: 563–569.
40.
go back to reference Tucker, G., R. Boyes, P. Bridenbaugh, and D. Moore. 1970. Binding of anilide-type local anesthetics in human plasma: I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology 33: 287.CrossRefPubMed Tucker, G., R. Boyes, P. Bridenbaugh, and D. Moore. 1970. Binding of anilide-type local anesthetics in human plasma: I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology 33: 287.CrossRefPubMed
41.
go back to reference Meunier, J., E. Goujard, A. Dubousset, K. Samii, and J. Mazoit. 2001. Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. Anesthesiology 95: 87.CrossRefPubMed Meunier, J., E. Goujard, A. Dubousset, K. Samii, and J. Mazoit. 2001. Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. Anesthesiology 95: 87.CrossRefPubMed
42.
go back to reference Brunton, L.L. (ed.). 2006. Goodman & Gilman’s the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill. Brunton, L.L. (ed.). 2006. Goodman & Gilman’s the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill.
43.
go back to reference Chaplan, S., F. Bach, S. Shafer, and T. Yaksh. 1995. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 83: 775–785.CrossRefPubMed Chaplan, S., F. Bach, S. Shafer, and T. Yaksh. 1995. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 83: 775–785.CrossRefPubMed
44.
go back to reference Arnér, S., U. Lindblom, B. Meyerson, and C. Molander. 1990. Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies. Pain 43: 287–297.CrossRefPubMed Arnér, S., U. Lindblom, B. Meyerson, and C. Molander. 1990. Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies. Pain 43: 287–297.CrossRefPubMed
Metadata
Title
Intra-articular (IA) Ropivacaine Microparticle Suspensions Reduce Pain, Inflammation, Cytokine, and Substance P Levels Significantly More than Oral or IA Celecoxib in a Rat Model of Arthritis
Authors
Barrett Rabinow
Jane Werling
Alison Bendele
Jerome Gass
Roy Bogseth
Kelly Balla
Paul Valaitis
Audrey Hutchcraft
Sabine Graham
Publication date
01-02-2015
Publisher
Springer US
Published in
Inflammation / Issue 1/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0006-z

Other articles of this Issue 1/2015

Inflammation 1/2015 Go to the issue